Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Nivolumab/Ipilimumab Misses Coprimary Endpoint in Adjuvant Melanoma Trial

November 20th 2019

The combination of nivolumab and ipilimumab did not show a statistically significant improvement in recurrence-free survival compared with single-agent nivolumab as an adjuvant treatment for patients who have had complete surgical removal of stage IIIB/C/D or stage IV melanoma and whose tumors expressed PD-L1

Vemurafenib/Cobimetinib Shows Long-Term OS Benefit in BRAF+ Melanoma

November 19th 2019

The combination of vemurafenib and cobimetinib led to a 5-year overall survival rate of nearly 40% in patients with BRAF V600E–mutant metastatic melanoma who had not received prior therapy with a BRAF inhibitor.

Dr. Long on Rationale for Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets

November 14th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma who have brain metastases.

Dr. Polsky on Potential Applications of ctDNA in Melanoma

November 9th 2019

David Polsky, MD, PhD, discusses potential applications of circulating tumor DNA as a biomarker in melanoma.

Dr. Luke on Treatment Options in Metastatic Melanoma

November 8th 2019

Jason J. Luke, MD, FACP, discusses the treatment landscape of metastatic melanoma.

Dr. Daud on Interferon Gamma as a Biomarker in Melanoma

November 8th 2019

Adil Daud, MD, clinical professor, Department of Medicine (Hematology/Oncology) and director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses research evaluating interferon gamma as a potential biomarker of response in melanoma.

Adjuvant Immunotherapy Combinations on Horizon for Melanoma

November 8th 2019

Quickly following on the approval of single agents, adjuvant immunotherapy combinations are quickly progressing through development, with promising signs of clinical activity seen in phase II studies, according to a presentation by Jeffrey S. Weber, MD, PhD, at the 37th Annual CFS®.

Dr. Weber on Biomarker Data From CheckMate-238 for Melanoma

November 7th 2019

Jeffrey S. Weber, MD, PhD, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.

Dr. Long on Including Patients With Melanoma Who Have Brain Mets on Clinical Trials

November 5th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses how to efficiently enroll patients with melanoma who have brain metastases in clinical trials.

Dr. Weber on the Future of Checkpoint Inhibitors in Melanoma

October 25th 2019

Jeffrey S. Weber, MD, PhD, discusses the future of checkpoint inhibitors in melanoma.

European Commission Approves 4-Week Nivolumab Dosing Schedule in Adjuvant Melanoma

October 24th 2019

The European Commission has approved nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.

Novel Immunotherapy Combos Target GITR to Step on the Gas

October 22nd 2019

Immunotherapies designed to exploit the host immune system to specifically target cancer cells exploded onto the oncology scene in the mid-1980s, when the first such agents started to show success in melanoma and renal cell carcinoma.

Dr. Long on Sequencing Local Therapy in Patients With Melanoma Who Have Brain Mets

October 21st 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the sequence of local therapy in patients with melanoma who have brain metastases.

Dr. Weber on Toxicity Data From CheckMate-238 Trial in Melanoma

October 18th 2019

Jeffrey S. Weber, MD, PhD, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Dr. Atkins on Long-Term Outcomes of the CheckMate-204 Trial in Melanoma

October 15th 2019

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses long-term outcomes of the CheckMate-204 trial in melanoma.

Dr. Long on Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets

October 12th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the long-term data from the phase II ABC study , in which investigators are comparing the efficacy of nivolumab in combination with ipilimumab versus single-agent nivolumab in patients with melanoma brain metastases.

Dr. Weber on Rationale for the CheckMate-238 Trial in Melanoma

October 8th 2019

Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

New Data Establish Long-Term Efficacy for 2 Modern Modalities in NSCLC and Melanoma

October 4th 2019

For nearly a decade, immunotherapy and molecularly targeted agents have been the focus of intense development. Now emerging evidence suggests that both modalities can deliver long-term benefits for patients, but the findings may prompt additional questions of how best to fit these transformative therapies into treatment landscapes.

Dr. Atkins on CA209-004 Trial Results in Advanced Melanoma

October 3rd 2019

Michael B. Atkins, MD, discusses results from the CA209-004 trial, which was a phase I study analyzing patients with advanced, unresectable melanoma treated with nivolumab plus ipilimumab.

Merkel Cell Carcinoma Study Matches TMB With Disease Drivers

October 3rd 2019

The molecular profile of Merkel cell carcinoma differs depending upon whether the malignancy is driven by ultraviolet light or by a virus and can be correlated with responses to immunotherapy, according to recent study findings.